Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Oncology
Anastasia Alataki, Mitch Dowsett
Summary: Endocrine therapies are the main treatment for hormone-dependent breast cancer, but HER2 signaling contributes to resistance and affects treatment efficacy. HER2 overexpression plays a role in resistance to endocrine therapies in breast cancer patients, impacting their clinical outcomes.
ENDOCRINE-RELATED CANCER
(2022)
Review
Biochemistry & Molecular Biology
Jose Luis Civico-Ortega, Isabel Gonzalez-Ruiz, Pablo Ramos-Garcia, David Cruz-Granados, Valerie Samayoa-Descamps, Miguel angel Gonzalez-Moles
Summary: The aim of this systematic review and meta-analysis was to assess the clinicopathological and prognostic significance of epidermal growth factor receptor (EGFR) overexpression in patients with oral squamous cell carcinoma (OSCC). A total of 50 primary-level studies (4631 patients) met the inclusion criteria. The findings support that immunohistochemical assessment of EGFR overexpression may serve as a useful prognostic biomarker for OSCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Jinhua Ding, Li Jiang, Zheng Xu, Yong Chen, Weizhu Wu, Jian Huang
Summary: This study investigated the prognostic value of the 8th edition AJCC prognostic staging system in Chinese patients with luminal B-like HER2-negative breast cancer. The results showed that the prognostic staging system could better evaluate the survival rates of breast cancer and contribute to personalized treatment approaches.
CANCER MANAGEMENT AND RESEARCH
(2022)
Review
Oncology
Rita Saude-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Summary: This article summarises the current knowledge about HER2 alterations in CRC and the potential of anti-HER2 therapies. Recent studies confirm the therapeutic potential of established and new anti-HER2 agents, as well as the utility of liquid biopsy and ctDNA analyses for HER2 detection. HER2 represents a valuable target for emerging anti-HER2 therapies.
CURRENT OPINION IN ONCOLOGY
(2022)
Article
Oncology
Anie Priscilla Masilamani, Alexandra Fischer, Susanne Schultze-Seemann, Irina Kuckuck, Isis Wolf, Franz Friedrich Dressler, Christian Gratzke, Philipp Wolf
Summary: The study developed a targeted toxin EGF-PE40, which showed significant cytotoxicity against EGFR-expressing bladder cancer cells with high specificity. The results indicated that EGF-PE40 could induce apoptosis to kill the bladder cancer cells effectively, suggesting its potential as a promising candidate for future bladder cancer treatment.
ANTICANCER RESEARCH
(2021)
Article
Chemistry, Analytical
Minghao Qiu, Yuqing Ren, Lumin Huang, Xueying Zhu, Tikai Liang, Meijin Li, Dianping Tang
Summary: A sensitive electrochemical immunoassay platform for quantitatively monitoring human epidermal growth factor receptor 2 (HER2) is developed using iron nitrogen-doped carbon (FeNC) nanozyme-modified screen-printed carbon electrode and chronoamperometry. The system demonstrates good amperometric response and can detect target HER2 as low as 4.5 pg/mL. FeNC nanozyme-based sensing strategy offers high specificity and long-term stability, providing a new opportunity for protein diagnostics.
Article
Oncology
Ivica Ratosa, Nika Dobnikar, Michele Bottosso, Maria Vittoria Dieci, William Jacot, Stephane Pouderoux, Domen Ribnikar, Lea Sinoquet, Valentina Guarneri, Tanja Znidaric, Amelie Darlix, Gaia Griguolo
Summary: Leptomeningeal metastases (LM) in patients with HER2+ breast cancer are rare but often fatal. This multicentric study retrospectively gathered data from 82 patients with advanced HER2+ breast cancer and LM. The study found that absence of neurological symptoms and receiving radiotherapy were associated with prolonged overall survival.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Pharmacology & Pharmacy
H. Qian, Wenzhi Huang, Y. Zhang, Xiaofei Cheng, C. Zhong, F. Tian, Ziang Chu, T. Zhou
Summary: This study aimed to investigate the association of epidermal growth factor receptor and human epidermal growth factor receptor 2 with colorectal cancer prognosis under FOLFOX chemotherapy. The results indicated that the upregulation of serum epidermal growth factor receptor and human epidermal growth factor receptor 2 may be a risk factor for poor prognosis of colorectal cancer.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Review
Oncology
Jane E. Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Allison Trail, Rebecca E. Waters, Jaffer Ajani
Summary: Human epidermal growth factor receptor-2 (HER2) is a well-known cancer target with various therapies available. However, the response and effectiveness of HER2-targeted agents differ among different tumor types, including gastric adenocarcinomas (GACs). GACs exhibit heterogeneity in HER2 expression, both within and between tumors, which poses challenges in assessing the efficacy of HER2-targeted agents. The recent approval of trastuzumab deruxtecan, an antibody drug conjugate, for refractory HER2-positive advanced GAC patients shows promise. Ongoing research aims to understand resistance patterns and intra-tumor heterogeneity to improve treatment outcomes. This review discusses the current status of HER2-targeted therapy in GACs and explores new therapies under investigation.
Article
Biochemistry & Molecular Biology
Faris Alrumaihi
Summary: A bioinformatic approach was used to screen compounds that can bind to the kinase domain of HER2. Three compounds with good binding affinity were identified, namely LAS_51187157, LAC_51217113, and LAC_51390233.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Oncology
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F. Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The US FDA approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy specifically for HER2-low metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Volkmar Mueller, Rupert Bartsch, Nancy U. Lin, Filippo Montemurro, Mark D. Pegram, Sara M. Tolaney
Summary: This systematic literature review provides a comprehensive overview of the epidemiology, unmet needs, and treatment landscape for patients with HER2+ metastatic breast cancer and brain metastases. There is a need for standardization of clinical trial design to ensure all types of brain metastases can access effective treatments.
CANCER TREATMENT REVIEWS
(2023)
Article
Medicine, Research & Experimental
Rohit Sharma, Manoj Kumbhakar, Archana Mukherjee
Summary: Human epidermal growth factor receptor 2 (HER2) is overexpressed in various types of cancer, with combination therapy using trastuzumab and pertuzumab antibodies showing improved survival outcomes in breast cancer patients. Radiolabeled and fluorescently labeled antibodies were used in in vitro studies to investigate binding synergism in HER2 overexpressing cell lines. The results showed enhanced uptake of pertuzumab and its F(ab')(2) fragments when combined with trastuzumab, indicating synergism in their binding to HER2.
MOLECULAR PHARMACEUTICS
(2021)